Division Faculty Labs
Larry Anderson, M.D., Ph.D.
My lab is interested in finding targets for T-cell therapy of multiple myeloma and other monoclonal hammopathies such as Waldenstrom’s macroglobulinemia. The ultimate goal of this research is to translate findings from tissue culture and mouse studies into immunotherapies for Myeloma patients. Thus far we have identified two potentially relevant peptides from the candidate myeloma antigen MAGE-C1 (CT-7), a cancer testis antigen, and we are also looking for epitopes from other candidate antigens. We are using various methods including reverse immunology as well as vaccination of HLA-A2 transgenic mice with gene-modified cellular vaccines to elicit T-cell responses. Another goal of the lab is to identify the targets recognized by T-cells in the setting of graft versus myeloma responses and graft versus Waldenstrom’s following allogeneic stem cell transplantation.
James Kim. M.D., Ph.D.
Dr. Kim’s laboratory focuses on how fundamental developmental pathways, such as Hedgehog, are involved in the initiation, growth, and metastases of cancers through the use of cancer mouse models and cell and molecular biological techniques. The laboratory also seeks to understand interactions of these pathways with each other and between tumor epithelia and stroma.
Elizabeth Maher, M.D., Ph.D.
Deepak Nijhawan, M.D., Ph.D.
Theodora Ross, M.D., Ph.D.
Website: Ross Lab
Our laboratory is interested in understanding mechanisms of transformation of normal cells to cancer cells and the use of that understanding in the clinic. Our focus is on three areas: First, we are interested in receptor tyrosine kinases and their connection to an endocytic protein called huntingtin-interacting protein 1 (HIP1) in cancer biology. Second, the role(s) of tyrosine kinase oncogenes in cancer initiation, maintenance, and drug resistance are being studied using humanized knock-in mouse models of leukemia. Finally, we are defining the molecular and cellular biology of families with a high risk for cancer in hopes that we can use this information in the general management of cancer-prone families.
David Wang, M.D., Ph.D.
Dr. Wang’s laboratory is focused on understanding the role of aberrant developmental pathway signaling in esophageal cancer and precursor lesions. In his clinic, Dr. Wang sees patients with esophageal cancer, gastric cancer, and other gastrointestinal malignancies.